Acknowledging Caronia: FDA Takes The First Step To Rethinking Off-Label Policy

FDA has gotten past the denial phase and now is listening to ideas on how to balance the need to preserve the integrity of the regulatory process with evolving interpretations of the First Amendment as it applies to commercial speech. That is slow but important progress – but towards what goal?